Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).

Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19.

2.

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators.

JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.

3.

Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.

Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz C, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA; TACT Investigators.

Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):508-16.

4.

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL.

Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.

5.

Design of the Trial to Assess Chelation Therapy (TACT).

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL.

Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.

6.

EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.

Ouyang P, Gottlieb SH, Culotta VL, Navas-Acien A.

Curr Cardiol Rep. 2015 Nov;17(11):96. doi: 10.1007/s11886-015-0656-y. Review.

PMID:
26364188
7.

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA.

Circulation. 2015 Mar 24;131(12):1047-53. doi: 10.1161/CIRCULATIONAHA.114.013774. Epub 2015 Feb 13.

8.

Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.

Peguero JG, Arenas I, Lamas GA.

Trends Cardiovasc Med. 2014 Aug;24(6):232-40. doi: 10.1016/j.tcm.2014.06.002. Epub 2014 Jun 12.

9.

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R.

J Am Heart Assoc. 2012 Oct;1(5):e002279. doi: 10.1161/JAHA.112.002279. Epub 2012 Oct 25. Erratum in: J Am Heart Assoc. 2015;4(10). pii: e001991. doi: 10.1161/JAHA.115.001991.

10.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

11.

Chelation therapy after the trial to assess chelation therapy: results of a unique trial.

Avila MD, Escolar E, Lamas GA.

Curr Opin Cardiol. 2014 Sep;29(5):481-8. doi: 10.1097/HCO.0000000000000096. Review.

12.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.

13.

Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).

Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA.

Circulation. 2017 May 16;135(20):1911-1921. doi: 10.1161/CIRCULATIONAHA.116.024632. Epub 2017 Feb 28.

PMID:
28246236
14.

Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective.

Kaul S.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):5-7. doi: 10.1161/CIRCOUTCOMES.113.000714. Epub 2014 Jan 14. No abstract available.

15.

Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?

Lamas GA, Ergui I.

Expert Rev Cardiovasc Ther. 2016 Aug;14(8):927-38. doi: 10.1080/14779072.2016.1180977. Epub 2016 May 5. Review.

16.

Chelation therapy for ischemic heart disease: a randomized controlled trial.

Knudtson ML, Wyse DG, Galbraith PD, Brant R, Hildebrand K, Paterson D, Richardson D, Burkart C, Burgess E; Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators.

JAMA. 2002 Jan 23-30;287(4):481-6.

PMID:
11798370
17.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group .

Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032038. doi: 10.1161/CIRCULATIONAHA.117.032038. [Epub ahead of print]

PMID:
29133604
18.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
19.

Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.

Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL.

JAMA. 2014 Dec 3;312(21):2234-43. doi: 10.1001/jama.2014.15825.

PMID:
25402757
20.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.

Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.

Supplemental Content

Support Center